← All drugs
Drug · FAERS side-effect profile with label screen

Amlodipine Besylate side effects: what 145,623 FDA adverse event reports show

Amlodipine Besylate · Katerzia · 1,176 reaction terms · 594,993 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Calcium channel blocker and may be

FDA label, Indications wording

Brand names

Katerzia

openFDA label

Who reports

145,623 reports · 69% serious · 13,152 with death outcome · 57% female

openFDA FAERS counts, all years, deduplication not applied

Used for

KATERZIA is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) KATERZIA is indicated for the treatment of hypertension in adults and children 6 years and older, to lower blood pressure.

FDA label, Indications and Usage

What it is

Amlodipine is a fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

PubChem CID 2162 (ChEBI)

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Likely indication confounding 11Reporting / coding artifact 2Lab value / disease marker 2Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,136 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Congenital hiatus hernia107134.7
103.4–175.6ROR 134.8 · calibrated p 2e-8 ✓
68.6 EB05 58.3 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=107 · ♀ 0% (drug 57%) · 100% cliniciannot reported in cached trials
Neurologic neglect syndrome21891.8
77.4–108.8ROR 91.9 · calibrated p 3e-7 ✓
55.7 EB05 49.8 · IC025 +5.4
3/3 methods agree
Not in label — unassessedserious n=218 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Carotid artery thrombosis22049.8
42.7–58.1ROR 49.9 · calibrated p 2e-5 ✓
37.0 EB05 33.0 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=220 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Adjustment disorder21628.4
24.6–32.9ROR 28.5 · calibrated p 4e-4 ✓
23.8 EB05 21.2 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=215 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Chronic kidney disease-mineral and bone disorder16826.5
22.5–31.2ROR 26.5 · calibrated p 5e-4 ✓
22.4 EB05 19.7 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=168not reported in cached trials
Nephrogenic anaemia72326.2
24.2–28.4ROR 26.3 · calibrated p 5e-4 ✓
22.2 EB05 20.9 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=722not reported in cached trials
Multiple drug therapy10725.9
21.1–31.9ROR 25.9 · calibrated p 6e-4 ✓
22.0 EB05 18.7 · IC025 +4.0
3/3 methods agree
Reporting / coding artifactserious n=106 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Hyperparathyroidism secondary36624.2
21.7–27.0ROR 24.3 · calibrated p 8e-4 ✓
20.8 EB05 19.1 · IC025 +4.2
3/3 methods agree
Not in label — unassessedserious n=365NCT00170950: 1/5,757 (0.0%) on Amlodipine Besylate (serious AE)
Blood pressure inadequately controlled66217.5
16.2–19.0ROR 17.6 · calibrated p 0.004 ✓
15.7 EB05 14.7 · IC025 +3.8
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=437NCT00170950: 1/5,757 (0.0%) on Amlodipine Besylate (serious AE)
Sedation complication26016.6
14.6–18.9ROR 16.6 · calibrated p 0.005 ✓
14.9 EB05 13.5 · IC025 +3.7
3/3 methods agree
Reporting / coding artifactserious n=260 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Nasal oedema16914.9
12.7–17.4ROR 14.9 · calibrated p 0.007 ✓
13.5 EB05 11.9 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=164 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Personality disorder23914.3
12.5–16.3ROR 14.3 · calibrated p 0.009 ✓
13.0 EB05 11.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=238 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Gingival hypertrophy13414.0
11.7–16.7ROR 14.0 · calibrated p 0.010 ✓
12.8 EB05 11.0 · IC025 +3.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
♀ 0% (drug 57%) · 100% cliniciannot reported in cached trials
Creatinine renal clearance decreased32212.4
11.1–13.9ROR 12.4 · calibrated p 0.015 ✓
11.5 EB05 10.4 · IC025 +3.3
3/3 methods agree
Lab value / disease markerserious n=315 · ♀ 100% (drug 57%)not reported in cached trials
Rebound acid hypersecretion23011.6
10.1–13.3ROR 11.6 · calibrated p 0.019 ✓
10.7 EB05 9.6 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=230not reported in cached trials
Nephrogenic systemic fibrosis22311.2
9.8–12.9ROR 11.3 · calibrated p 0.022 ✓
10.4 EB05 9.3 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=222not reported in cached trials
Schizoaffective disorder12710.9
9.1–13.1ROR 10.9 · calibrated p 0.025 ✓
10.0 EB05 8.6 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=127 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
End stage renal disease1,20310.0
9.4–10.6ROR 10.1 · calibrated p 0.032 ✓
9.4 EB05 8.9 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious PRR 7.8not reported in cached trials
Distributive shock1439.9
8.4–11.7ROR 9.9 · calibrated p 0.035 ✓
9.2 EB05 8.0 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=143 · 100% cliniciannot reported in cached trials
Essential hypertension1669.8
8.4–11.5ROR 9.8 · calibrated p 0.036 ✓
9.1 EB05 8.0 · IC025 +2.9
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=148NCT00170950: 1/5,740 (0.0%) on Amlodipine Besylate (serious AE)
Blood pressure systolic abnormal1519.2
7.8–10.9ROR 9.2 · calibrated p 0.043 ✓
8.6 EB05 7.5 · IC025 +2.8
3/3 methods agree
Likely indication confounding
term in indications
serious n=149 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Burns second degree1008.7
7.1–10.6ROR 8.7 · calibrated p 0.054
8.0 EB05 6.8 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=96 · ♀ 0% (drug 57%) · 100% cliniciannot reported in cached trials
Skin induration1168.5
7.1–10.3ROR 8.5 · calibrated p 0.057
7.9 EB05 6.7 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=113 · 100% cliniciannot reported in cached trials
Breath sounds abnormal2718.3
7.4–9.4ROR 8.3 · calibrated p 0.060
7.8 EB05 7.1 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=262not reported in cached trials
Carotid artery stenosis1868.0
6.9–9.3ROR 8.0 · calibrated p 0.068
7.5 EB05 6.6 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=186 · 100% clinicianNCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE)
Hyperphosphataemia1128.0
6.6–9.6ROR 8.0 · calibrated p 0.069
7.4 EB05 6.3 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=112 · ♀ 0% (drug 57%) · 100% cliniciannot reported in cached trials
Renal failure chronic4017.8
7.0–8.6ROR 7.8 · calibrated p 0.073
7.3 EB05 6.8 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious PRR 6.1NCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE)
Benign prostatic hyperplasia2597.5
6.6–8.5ROR 7.5 · calibrated p 0.081
7.1 EB05 6.4 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=253 · ♀ 0% (drug 57%)NCT00170950: 13/5,740 (0.2%) on Amlodipine Besylate (serious AE)
Hyperlipidaemia5917.4
6.8–8.1ROR 7.4 · calibrated p 0.083
7.1 EB05 6.6 · IC025 +2.7
3/3 methods agree
Likely indication confounding
term in indications
serious PRR 6.2not reported in cached trials
Blood pressure diastolic abnormal1186.9
5.7–8.3ROR 6.9 · calibrated p 0.106
6.5 EB05 5.5 · IC025 +2.4
3/3 methods agree
Likely indication confounding
term in indications
serious n=116 · ♀ 100% (drug 57%) · 100% cliniciannot reported in cached trials
Lacunar infarction1066.6
5.5–8.1ROR 6.6 · calibrated p 0.118
6.2 EB05 5.3 · IC025 +2.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=105 · ♀ 0% (drug 57%) · 100% cliniciannot reported in cached trials
Ischaemic cardiomyopathy1376.6
5.6–7.9ROR 6.6 · calibrated p 0.118
6.2 EB05 5.4 · IC025 +2.4
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=136 · ♀ 0% (drug 57%) · 100% clinicianNCT00170950: 1/5,740 (0.0%) on Amlodipine Besylate (serious AE)
Ventricular hypertrophy1116.6
5.4–7.9ROR 6.6 · calibrated p 0.121
6.2 EB05 5.3 · IC025 +2.3
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=111 · ♀ 0% (drug 57%) · 100% cliniciannot reported in cached trials
Hemiplegia3566.4
5.7–7.1ROR 6.4 · calibrated p 0.128
6.1 EB05 5.6 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious PRR 5.2 · ♀ 80% (drug 57%)NCT00170950: 1/5,740 (0.0%) on Amlodipine Besylate (serious AE)
Arterial occlusive disease3346.3
5.7–7.0ROR 6.3 · calibrated p 0.132
6.0 EB05 5.5 · IC025 +2.4
3/3 methods agree
Not in label — unassessedserious PRR 5.2NCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE)
Blood calcium decreased4706.2
5.7–6.8ROR 6.2 · calibrated p 0.137
6.0 EB05 5.5 · IC025 +2.4
3/3 methods agree
Likely indication confounding
term in indications
serious PRR 5.9 · ♀ 81% (drug 57%)not reported in cached trials
Blood phosphorus increased1136.2
5.1–7.5ROR 6.2 · calibrated p 0.142
5.8 EB05 5.0 · IC025 +2.2
3/3 methods agree
Lab value / disease markerserious n=106 · ♀ 0% (drug 57%) · 100% cliniciannot reported in cached trials
Gangrene2476.1
5.3–6.9ROR 6.1 · calibrated p 0.147
5.8 EB05 5.2 · IC025 +2.3
3/3 methods agree
Not in label — unassessedserious n=246 · ♀ 100% (drug 57%)NCT00170950: 1/5,757 (0.0%) on Amlodipine Besylate (serious AE)
Aortic stenosis1416.0
5.1–7.1ROR 6.0 · calibrated p 0.150
5.7 EB05 5.0 · IC025 +2.2
3/3 methods agree
Labeled adverse reaction
exact term
serious n=141 · ♀ 0% (drug 57%) · 100% clinicianNCT00170950: 3/5,740 (0.1%) on Amlodipine Besylate (serious AE)
Diastolic dysfunction1256.0
5.0–7.2ROR 6.0 · calibrated p 0.153
5.7 EB05 4.9 · IC025 +2.2
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=124not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Kidney injury9,5473.13.0–3.1signal
Hyponatraemia1,5972.92.8–3.0signal
Heart failure3,3362.72.6–2.8signal
Stroke4,3422.52.5–2.6signal
Anaemia4,9802.42.3–2.5signal
Myocardial infarction3,3052.32.3–2.4signal
Gi bleeding2,9022.32.2–2.4signal
Rhabdomyolysis / myopathy1,2622.32.1–2.4signal
Arrhythmia / qt2,9942.22.2–2.3signal
Fall / fracture5,7832.22.2–2.3signal
Hypoglycaemia1,3222.01.9–2.1raised
Interstitial lung disease1,2962.01.9–2.1raised
Serious infection10,3161.91.9–2.0raised
Hyperglycaemia / diabetes4,3431.81.8–1.9raised
Thrombocytopenia2,4351.61.5–1.7raised
Depression3,0331.61.5–1.6raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Amlodipine Besylate as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (11 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Fatigue (tiredness)9,7311.8
1.8–1.8ROR 1.9 · calibrated p 0.872
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.8NCT00170950: 3/5,740 (0.1%) on Amlodipine Besylate (serious AE)
Nausea8,3451.5
1.5–1.6ROR 1.6 · calibrated p 0.681
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.6NCT00170950: 9/5,740 (0.2%) on Amlodipine Besylate (serious AE)
Diarrhoea (diarrhea)7,9131.8
1.7–1.8ROR 1.8 · calibrated p 0.845
1.8 EB05 1.7 · IC025 +0.8Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.7NCT00170950: 17/5,740 (0.3%) on Amlodipine Besylate (serious AE)
Dyspnoea (shortness of breath)7,8342.0
2.0–2.1ROR 2.1 · calibrated p 0.979
2.0 EB05 2.0 · IC025 +1.0Not in label — unassessedage-adj. PRR 1.8 · serious PRR 1.9NCT00170950: 40/5,740 (0.7%) on Amlodipine Besylate (serious AE)
Drug ineffective (drug did not work)7,0770.8
0.8–0.8ROR 0.8 · calibrated p 0.162
0.8 EB05 0.8 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 1.0not reported in cached trials
Pain6,8091.6
1.6–1.6ROR 1.6 · calibrated p 0.725
1.6 EB05 1.6 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.9 · serious PRR 1.6NCT00170950: 21/5,740 (0.4%) on Amlodipine Besylate (serious AE)
Dizziness6,5541.9
1.9–2.0ROR 1.9 · calibrated p 0.916
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.9NCT01252563: 45/13,343 (0.3%) on Amlodipine Besylate
Headache6,4521.5
1.5–1.5ROR 1.5 · calibrated p 0.649
1.5 EB05 1.5 · IC025 +0.5Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.6NCT01252563: 14/13,343 (0.1%) on Amlodipine Besylate
Asthenia (weakness)5,7602.2
2.2–2.3ROR 2.3 · calibrated p 0.915
2.2 EB05 2.2 · IC025 +1.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.8 · serious PRR 2.0NCT00170950: 9/5,740 (0.2%) on Amlodipine Besylate (serious AE)
Fall5,3982.4
2.3–2.4ROR 2.4 · calibrated p 0.852
2.3 EB05 2.3 · IC025 +1.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.7 · serious PRR 2.1NCT00170950: 13/5,740 (0.2%) on Amlodipine Besylate (serious AE)
Pneumonia (lung infection)5,3832.4
2.4–2.5ROR 2.5 · calibrated p 0.824
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.0 · serious PRR 2.1NCT01252563: 7/13,343 (0.1%) on Amlodipine Besylate (serious AE)
Vomiting5,3041.6
1.6–1.7ROR 1.7 · calibrated p 0.744
1.6 EB05 1.6 · IC025 +0.7Not in label — unassessedage-adj. PRR 1.7 · serious PRR 1.7NCT00170950: 13/5,740 (0.2%) on Amlodipine Besylate (serious AE)
Off label use (used outside approved label)5,3020.9
0.9–0.9ROR 0.9 · calibrated p 0.227
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 1.0not reported in cached trials
Hypertension (high blood pressure)5,1673.6
3.5–3.7ROR 3.7 · calibrated p 0.446
3.5 EB05 3.4 · IC025 +1.8
3/3 methods agree
Likely indication confounding
term in indications
age-adj. PRR 3.1 · serious PRR 3.1NCT00170950: 3/5,740 (0.1%) on Amlodipine Besylate (serious AE)
Death4,8470.8
0.8–0.8ROR 0.8 · calibrated p 0.185
0.8 EB05 0.8 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Outcome field, not a reactionage-adj. PRR 0.7 · serious PRR 0.7NCT01252563: 1/13,343 (0.0%) on Amlodipine Besylate (serious AE)

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Amlodipine (dihydropyridine CCBs) ↔ Peripheral oedema.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Amlodipine Besylate?

In FDA FAERS, the most frequently co-reported reaction terms for Amlodipine Besylate are fatigue, nausea, diarrhoea, dyspnoea, pain, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Amlodipine Besylate have an FDA boxed warning?

No. The FDA label retrieved for Amlodipine Besylate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Amlodipine Besylate causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.